期刊文献+

超临界流体抗溶剂法制备多肽微粉

Preparation of polypeptide micro-powder by supercritical antisolvent process
下载PDF
导出
摘要 利用自制的超临界流体抗溶剂装置,以多肽化合物为模型药物,研究压力、温度、进样速率和样品浓度等工艺参数对微粉粒径的影响,并采用扫描电镜、热重分析仪、X射线衍射仪等对制备的微粉进行表征。结果表明:压力、温度和样品浓度3个工艺参数对微粉的粒径没有显著性影响,微粉微观形貌主要为球形;微粉热稳定性未发生明显变化;微粉主要为无定形结构;制备得到空气动力学粒径约为1.0 pum的微粉,符合吸入式给药对微粉粒径的要求。 In this paper,the polypeptide powder was prepared by an experimental apparatus for supercritical anti solvent process,and the effects of process parameters including pressure,temperature,flow rate and concentration on the particle size were investigated experimentally.The characteristics of the powder were carried out by SEM,TGA and XRD.The results show that there is no signifigant effect of pressure,temperature and concentration on particle size and the morphology of micro-particles prepared is mainly spherical.There is no significant change in the thermal stability of micro-powder.The powder is mainly amorphous structure.The aerodynamic particle size of the powder is about 1.0 jxm,which is suitable for inhalation delivery system.
作者 黄永鹏 陈博 唐慧 钟辉 孟祥燕 焦剑岚 HUANG Yongpeng;CHEN Bo;TANG Hui;ZHONG Hui;MENG Xiangyan;JIAO Jianlan(Research Institute of Chemical Defense,Beijing 102205,China)
机构地区 防化研究院
出处 《中国粉体技术》 CAS CSCD 2020年第2期41-47,共7页 China Powder Science and Technology
基金 国防预先研究项目,编号:LD4B04
关键词 吸入式给药 超临界流体抗溶剂 多肽化合物 微粉 inhalation drug delivery supercritical antisolvent process polypeptide microparticles
  • 相关文献

参考文献3

二级参考文献65

  • 1王鈜艳,刘宗章,张敏华.超临界抗溶剂技术及其在药物方面的应用[J].化工进展,2004,23(7):705-709. 被引量:7
  • 2李颖,潘卫三,陈士林,杨大坚,陈新滋,徐宏喜.葛根素磷脂复合物的制备及其固体分散体研究[J].中国药学杂志,2006,41(15):1162-1167. 被引量:41
  • 3陈桂良,侯惠民.吸入用气雾剂雾粒测定方法的评价[J].中国医药工业杂志,2007,38(3):194-199. 被引量:24
  • 4Laube BL, Janssens HM, de Jongh FH, et al. What thepulmonary specialist should know about the new inhalationtherapies. ERS/ISAM task force report [J]. Eur Respir J,2011,37(6):1308-1331.
  • 5金方、侯曙光译,呼吸道药物递送的基本理论与实践[M].北京:化学工业出版社,2011: 222-223.
  • 6Clarke MJ, Bynm J,Taniforth N. Physicochemical factorsgoverning the performance of nedocromil sodium as a powderaerosol[J]. J Pharm Sci, 2000,89(9):1160-1169.
  • 7郑昕,LouiseR,陈昱,等.含福莫特罗的MDI的研究进展[J].国际医药商情,2012,12:28-30.
  • 8Cazzola M, Spina D, Matera MG. The use of bronchodilatorsin stable chronic obstructive pulmonary disease[J]. PulmPharmaco Ther, 1997,10(3):129-144.
  • 9Laforce C, Aunlann J, de Teresa Parrefiol, et al. Sustained 24-hour efficacy of once daily indacaterol(300mug)in patientswith chronic obstructive pulmonary disease: A randomized,crossover study[J]. Pulm Pharmaco Ther, 2011, 24(1):162-168.
  • 10Vail Ncord J, Smeets J, Drenth B, et al. 24-hour bronchodilationfollowing a single dose of the novel beta 2-agonist oiodatcrol inCOPD[J]. Pulm Pharmaco Ther, 2011, 24(6):666-672.

共引文献55

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部